Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

ByNancy A. Dreyer, PhD,Sebastian Schneeweiss, MD,Barbara J. McNeil, MD,Marc L. Berger, MD,Alec M. Walker, MD,Daniel A. Ollendorf, MPH,Richard E. Gliklich, MD,for the GRACE Initiative

June 4th 2010

The GRACE principles lay out 3 questions to help healthcare providers, patients, and other decision makers evaluate the quality of noninterventional comparative effectiveness studies.

Do Drug Formulary Policies Reflect Evidence of Value?

ByPeter J. Neumann, ScD,Pei-Jung Lin, MS,Dan Greenberg, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD,Edward Mansley, PhD,Milton C. Weinstein, PhD,Allison B. Rosen, MD, ScD

January 1st 2006

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

ByPamela B. Landsman, MPH, DrPH,Winnie Yu, PharmD,XiaoFeng Liu, PhD,Steven M. Teutsch, MD,Marc L. Berger, MD

October 1st 2005

Indirect Cost of Ischemic Heart Disease to Employers

ByBruce Sherman, MD. Author Reply by Christine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Marc L. Berger, MD,Steven M. Teutsch, MD, MPH

April 1st 2001

Indirect Cost of Ischemic Heart Disease to Employers

ByChristine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Steven M. Teutsch, MD, MPH,Albert I. Wertheimer, PhD, MBA,Marc L. Berger, MD

January 1st 2001

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

ByRobert S. Epstein, MD, MS,Susan Garrahan,Linda Nelsen, MS,Pamela Laber,Eve Slater, MD,Marc L. Berger, MD

December 1st 1996

Latest Updated Articles

Do Drug Formulary Policies Reflect Evidence of Value?
January 1st 2006
Indirect Cost of Ischemic Heart Disease to Employers
January 1st 2001
The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia
December 1st 1996
Indirect Cost of Ischemic Heart Disease to Employers
April 1st 2001
GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
June 4th 2010
Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization
October 1st 2005

Marc L. Berger, MD

Articles by Marc L. Berger, MD

GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness

Do Drug Formulary Policies Reflect Evidence of Value?

Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization

Indirect Cost of Ischemic Heart Disease to Employers

Indirect Cost of Ischemic Heart Disease to Employers

The Cholesterol Population Model: US Population Requirements for Treatment of Hypercholesterolemia

Latest Updated Articles

Trending on AJMC

Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD